Table 3.
Change in HbA1c by treatment group, age, cardiovascular disease and nephropathy
| Treatment group | n | Pre-HbA1c (mean±SD) | Post-HbA1c (mean±SD) | Change*† |
|---|---|---|---|---|
| U-500R only (group A) | 209 | 9.2±1.6 | 8.4±1.4 | −0.78±1.50 |
| U-500R with overlapping U-100 (group B) | 236 | 9.2±1.9 | 8.6±1.9 | −0.60±1.74 |
| Overall | 445 | 9.2±1.7 | 8.5±1.7 | −0.68±1.63 |
| Age group (years) | ||||
| <65 | 331 | 9.4±1.7 | 8.7±1.8 | −0.67±1.66 |
| ≥65 | 114 | 8.6±1.6 | 7.9±1.3 | −0.71±1.56 |
| Cardiovascular disease | ||||
| Yes | 175 | 9.1±1.7 | 8.4±1.7 | −0.68±1.63 |
| No | 270 | 9.2±1.8 | 8.5±1.7 | −0.68±1.64 |
| Nephropathy | ||||
| Yes | 187 | 9.1±1.6 | 8.5±1.8 | −0.55±1.62 |
| No | 258 | 9.3±1.8 | 8.5±1.6 | −0.78±1.64 |
*Unadjusted p values are all p<0.0001, compares endpoint HbA1c with baseline HbA1c values.
†LS mean changes±SE, adjusted for baseline HbA1c values.
Group A, −0.78±0.10; group B, −0.60±0.09 (p=0.175).
<65 years, −0.58±0.08; ≥65 years, −0.98±0.13 (p=0.011).
Cardiovascular disease=yes, −0.72±0.10; no, −0.66±0.09 (p=0.665).
Nephropathy=yes, −0.60±0.10; no, −0.74±0.09 (p=0.322).
HbA1c, glycated hemoglobin; LS, least squares; n, number of patients.